AFP and neoplasm: Primary tumor site, response to previous platinum-based therapy, IGCCCG risk score, 2 or more chemotherapy lines before HDCT, and serum tumor marker levels (B-HCG and AFP) are major prognostic factors in these models.[13,15–17] However, it should be noted that the patient groups represented in these models showed heterogeneity among studies.